Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in ...

Summary by Hastings Tribune
Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patientsTrial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM

2 Articles

Hastings TribuneHastings Tribune
Center

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in ...

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patientsTrial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM

·Nebraska, United States
Read Full Article
WBOC 16WBOC 16
Center

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

WBOC 16 broke the news on Tuesday, April 21, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Hastings, Nebraska icon

Hastings, Nebraska

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal